Highly accurate Skin-Specific methylome analysis algorithm as a platform to screen and validate therapeutics for healthy aging [DS4]. Highly accurate Skin-Specific methylome analysis algorithm as a platform to screen and validate therapeutics for healthy aging [DS4]

In the present study, we developed a highly accurate Skin-Specific DNAm age predictor, using DNAm data obtained from 508 human skin samples. Based on the analysis of 2,266 CpG sites, we accurately calculated the DNAm age of cultured skin cells, and human skin biopsies. Age estimation was sensitive to the biological age of the donor, cell passage, skin disease status, as well as treatment with senotherapeutic drugs. Overall design: Analyze changes in the methylation profile of human progeria dermal fibroblasts treated for 72 hours with 1.25uM ABT-263, 5uM ABT-263, 100nM Rapamycin compared to no treatment. Sample 1: human progeria dermal fibroblast, no treatment, in triplicate Sample 2: human progeria dermal fibroblast, treated with 1.25uM ABT-263, in triplicate Sample 3: human progeria dermal fibroblast, treated with 5uM ABT-263, in triplicate Sample 4: human progeria dermal fibroblast, treated with 100nM Rapamycin, in triplicate

本研究依托508例人类皮肤样本的DNA甲基化（DNAm）数据，构建了一款高精度的皮肤特异性DNA甲基化年龄预测器。通过对2266个CpG位点的分析，我们可精准测算培养皮肤细胞与人类皮肤活检组织的DNA甲基化年龄。该年龄估算结果对供体生物学年龄、细胞传代代数、皮肤疾病状态以及衰老靶向治疗药物处理均具有敏感性。
实验整体设计：分析经1.25μM ABT-263、5μM ABT-263、100nM雷帕霉素（Rapamycin）处理72小时的人类早衰症真皮成纤维细胞，与未处理对照组的甲基化谱差异。
样本1：未处理的人类早衰症真皮成纤维细胞，设置3次生物学重复
样本2：经1.25μM ABT-263处理的人类早衰症真皮成纤维细胞，设置3次生物学重复
样本3：经5μM ABT-263处理的人类早衰症真皮成纤维细胞，设置3次生物学重复
样本4：经100nM雷帕霉素（Rapamycin）处理的人类早衰症真皮成纤维细胞，设置3次生物学重复